NCT01826916View on ClinicalTrials.gov

EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 1, 2003

Primary Completion Date

December 1, 2005

Study Completion Date

January 1, 2006

Conditions
Hereditary Angioedema (HAE)
Interventions
DRUG

DX-88 (ecallantide)

solution for injection 10 mg/mL

Sponsors

Lead Sponsor

Shire
All Listed Sponsors
lead

Shire

INDUSTRY

NCT01826916 - EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema | Biotech Hunter | Biotech Hunter